| 4:00–8:00 PM | Registration |
| 6:00–8:00 PM | Welcome Mixer |
| 7:00–8:00 AM | Breakfast |
| 8:00–9:00 AM | Welcome and Keynote Address |
| Helen H. Hobbs †, University of Texas Southwestern Medical Center Genetic Determinants of Chronic Liver Disease Progression |
| 9:00–11:15 AM | Role of Intrahepatic Lipid Metabolism in Steatotic Liver Diseases |
| Jay D. Horton, University of Texas Southwestern Medical Center Role of Intrahepatic Lipid Metabolism in Steatotic Liver Diseases |
| Peter A. Crawford †, University of Minnesota Ketogenesis and Fatty Acid Synthesis |
| Kathryn E. Wellen †, University of Pennsylvania New and Surprising Directions in de novo Lipogenesis |
| Brian N. Finck †, Washington University Interorgan Communication and Hepatic Lipogenesis |
| Short Talk(s) Chosen from Abstracts |
| 9:30–9:50 AM | Coffee Break |
| 11:15–12:15 PM | Panel Discussion 1: What will be the Residual Risk if Patients are Placed in Incretin Therapy for Obesity? Then, What is the Residual Risk in MASH? |
| 11:15–1:00 PM | Poster Setup |
| 11:15–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing |
| 2:30–4:30 PM | Symposia Spotlight 1: Late-breaking research presentations selected from abstract submissions |
| Short Talks Chosen from Abstracts |
| 4:30–5:00 PM | Coffee Available |
| 5:00–7:00 PM | Molecular Drivers of Chronic Liver Disease |
| Ana Maria Cuervo †, Albert Einstein College of Medicine Role of Autophagy in Chronic Liver Disease |
| Peng Li †, Zengzhou University and Tsinghua University Role of Lipid Droplet Proteins in MASLD |
| Orian S Shirihai †, David Geffen School of Medicine at UCLA Mitochondrial Function in Chronic Liver Disease |
| Short Talk(s) Chosen from Abstracts |
| 7:00–8:00 PM | Social Hour with Dinner |
| 7:30–10:00 PM | Posters |
| 7:00–8:00 AM | Breakfast |
| 8:00–11:00 AM | Emerging Therapeutic Approaches to Treat Chronic Liver Diseases |
| Bei B. Zhang, Novo Nordisk Unraveling Complex Biology and Improving Cardiometabolic Health with New Therapies |
| Erik Ingelsson †, Wave Life Sciences Silencing INHBE to Achieve Healthy, Sustainable Weight Loss through Fat Burning, and Muscle Maintenance |
| Ruth E. Gimeno †, Eli Lilly and Company Incretin therapies in MASLD |
| Gerald I. Shulman †, Yale University School of Medicine Role of Uncouplers in Preventing MASLD Progression and Fibrosis |
| Short Talk(s) Chosen from Abstracts |
| 9:00–9:20 AM | Coffee Break |
| 11:00–12:00 PM | Panel Discussion 2: Is Weight Loss Induced Loss in Muscle Mass a Problem? |
| 11:00–1:00 PM | Poster Setup |
| 11:00–5:00 PM | On Own for Lunch |
| 1:00–10:00 PM | Poster Viewing |
| 3:00–4:30 PM | Career Roundtable |
| 4:30–5:00 PM | Coffee Available |
| 5:00–7:00 PM | Peripheral Organ Contribution and Pathogenesis of Liver Fibrosis |
| David A Brenner †, Sanford Burnham Prebys Molecular Events Leading to Stellate Cell Activation and Fibrosis in Chronic Liver Disease |
| Timo D Müller †, Helmholtz Munich Talk Title to be Announced |
| Liming Pei †, Children's Hospital of Philadelphia/University of Pennsylvania Pathogenesis and Mechanisms Underlying Fontan-Associated Liver Disease (FALD) |
| Sarah Ewald †, University of Virginia Cachexia and Hepatic Fibrosis |
| Short Talk(s) Chosen from Abstracts |
| 7:00–8:00 PM | Social Hour with Dinner |
| 7:30–10:00 PM | Posters |
| 7:00–8:00 AM | Breakfast |
| 8:00–11:00 AM | Weight Loss and Exercise in MASLD Progression |
| Samuel Klein, Washington University School of Medicine Metabolic and Hepatic Implications of Weight Loss |
| Arun J. Sanyal †, Virginia Commonwealth University Medical Center How Much Weight Loss is Needed to Effectively Impact MASLD and Fibrosis |
| Juleen R. Zierath †, Karolinska Institutet Exercise Medicine for MASLD |
| Short Talk(s) Chosen from Abstracts |
| 9:00–9:20 AM | Coffee Break |
| 11:00–5:00 PM | On Own for Lunch |
| 2:30–4:30 PM | Symposia Spotlight 2: Late-breaking research presentations selected from abstract submissions |
| Short Talks Chosen from Abstracts |
| 4:30–5:00 PM | Coffee Available |
| 5:00–6:45 PM | Role of Peripheral Organs in Chronic Liver Disease Progression |
| Caterina Conte †, San Raffaele Roma Open University Sarcopenia in Obesity and MASLD: Definition and Clinical Implications |
| Saswata Talukdar †, Merck Effect of Myostatin and Activin Inhibition on Muscle Mass, Strength and Function |
| Amalia Gastaldelli †, Institute of Clinical Physiology Linking Glucose Metabolism to MASLD Progression |
| Short Talk(s) Chosen from Abstracts |
| 6:45–7:00 PM | Meeting Wrap-Up: Outcomes and Future Directions (Organizers) |
| 7:00–8:00 PM | Social Hour with Dinner |
| 8:00–11:00 PM | Entertainment |
| 8:00–11:00 PM | Cash Bar |
| 12:00–11:59 PM | Departure |